Tumor heterogeneity: preclinical models, emerging technologies, and future applications.

Proietto, Marco; Crippa, Martina; Damiani, Chiara; Pasquale, Valentina; Sacco, Elena; Vanoni, Marco; Gilardi, Mara

Proietto, Marco; Crippa, Martina; Damiani, Chiara; Pasquale, Valentina; Sacco, Elena; Vanoni, Marco; Gilardi, Mara.

Afiliação

Proietto M; Next Generation Sequencing Core, The Salk Institute for Biological Studies, La Jolla, CA, United States.
Crippa M; Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, United States.
Damiani C; NOMIS Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, CA, United States.
Pasquale V; Vita-Salute San Raffaele University, Milan, Italy.
Sacco E; Experimental Imaging Center, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Vanoni M; Infrastructure Systems Biology Europe /Centre of Systems Biology (ISBE/SYSBIO) Centre of Systems Biology, Milan, Italy.
Gilardi M; Department of Biotechnology and Biosciences, School of Sciences, University of Milano-Bicocca, Milan, Italy.

Front Oncol ; 13: 1164535, 2023.

Article em En | MEDLINE | ID: mdl-37188201

Palavras-chave

heterogeneity models; human in vitro models; tumor heterogeneity; tumor immune microenvironment; tumor microenvironment (TME)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google